MCID: SYS070
MIFTS: 36

Systemic Epstein-Barr Virus-Positive T-Cell Lymphoma of Childhood

Categories: Blood diseases, Cancer diseases, Immune diseases

Aliases & Classifications for Systemic Epstein-Barr Virus-Positive T-Cell Lymphoma of...

MalaCards integrated aliases for Systemic Epstein-Barr Virus-Positive T-Cell Lymphoma of Childhood:

Name: Systemic Epstein-Barr Virus-Positive T-Cell Lymphoma of Childhood 12 15
Ebv-Positive T-Cell Lymphoproliferative Disorder of Childhood 12 17
Systemic Ebv-Positive T-Cell Lymphoma of Childhood 12
Lymphoproliferative Disorders 43

Classifications:



External Ids:

Disease Ontology 12 DOID:0070324
MeSH 43 D008232
NCIt 49 C80374
SNOMED-CT 67 450906003
ICD10 32 D47.9

Summaries for Systemic Epstein-Barr Virus-Positive T-Cell Lymphoma of...

Disease Ontology : 12 A pediatric lymphoma that is characterized by monoclonal expansion of Epstein-Barr virus-positive T cells with an activated cytotoxic phenotype in tissues or peripheral blood.

MalaCards based summary : Systemic Epstein-Barr Virus-Positive T-Cell Lymphoma of Childhood, also known as ebv-positive t-cell lymphoproliferative disorder of childhood, is related to lymphomatoid granulomatosis and chronic nk-cell lymphocytosis. An important gene associated with Systemic Epstein-Barr Virus-Positive T-Cell Lymphoma of Childhood is TIA1 (TIA1 Cytotoxic Granule Associated RNA Binding Protein), and among its related pathways/superpathways are NF-kappaB Signaling and Cell adhesion molecules (CAMs). The drugs Mycophenolic acid and Azathioprine have been mentioned in the context of this disorder. Affiliated tissues include t cells, b cells and bone marrow, and related phenotypes are Increased viability with MLN4924 (a NAE inhibitor) and Increased viability with MLN4924 (a NAE inhibitor)

Related Diseases for Systemic Epstein-Barr Virus-Positive T-Cell Lymphoma of...

Diseases related to Systemic Epstein-Barr Virus-Positive T-Cell Lymphoma of Childhood via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 656)
# Related Disease Score Top Affiliating Genes
1 lymphomatoid granulomatosis 32.4 TIA1 GZMB
2 chronic nk-cell lymphocytosis 31.6 NCAM1 CD7
3 t-cell large granular lymphocyte leukemia 31.6 NCAM1 GZMB CD8A
4 lymphomatoid papulosis 31.2 TIA1 GZMB
5 primary cutaneous anaplastic large cell lymphoma 30.9 TIA1 GZMB
6 angioimmunoblastic t-cell lymphoma 30.4 TIA1 GZMB
7 reticulosarcoma 30.3 TIA1 GZMB
8 composite lymphoma 30.2 TIA1 GZMB
9 orbit lymphoma 30.1 TIA1 NCAM1
10 prolymphocytic leukemia 29.9 CR2 CD7
11 pediatric lymphoma 29.8 TIA1 NCAM1
12 peripheral t-cell lymphoma 29.8 TIA1 NCAM1 GZMB CD8A
13 mycosis fungoides 29.8 TIA1 NCAM1 GZMB CD7
14 t-cell lymphoma, subcutaneous panniculitis-like 29.6 TIA1 GZMB CD7
15 hepatosplenic t-cell lymphoma 29.6 TIA1 GZMB CD7
16 leukemia, chronic lymphocytic 29.5 NCAM1 CR2 CD8A CD7 CD2
17 pancytopenia 29.5 NCAM1 CD8A CD7 CD2
18 oral hairy leukoplakia 29.4 CR2 CD8A
19 acute leukemia 29.3 NCAM1 CD8A CD7
20 autoimmune glomerulonephritis 29.3 GZMB CD8A
21 panniculitis 29.2 TIA1 NCAM1 GZMB CD8A
22 parapsoriasis 29.2 CD8A CD7 CD2
23 b cell deficiency 29.1 CR2 CD8A
24 nasal cavity lymphoma 29.0 TIA1 NCAM1 GZMB CD2
25 lymphoblastic lymphoma 29.0 CD8A CD7
26 leukemia, acute myeloid 29.0 NCAM1 CD8A CD7 CD2
27 sezary's disease 28.7 TIA1 NCAM1 CD8A CD7 CD2
28 t-cell adult acute lymphocytic leukemia 28.7 TIA1 CD8A CD7 CD2
29 follicular mucinosis 28.7 CD8A CD7 CD2
30 aggressive nk-cell leukemia 28.7 TIA1 NCAM1 GZMB CD7 CD2
31 lymphoma, non-hodgkin, familial 28.6 NCAM1 GZMB CR2 CD8A CD7 CD2
32 human immunodeficiency virus infectious disease 28.5 NCAM1 GZMB CR2 CD8A
33 lethal midline granuloma 28.3 TIA1 NCAM1 GZMB CD7 CD2
34 celiac disease 1 28.1 TIA1 NCAM1 GZMB CD8A CD7
35 methotrexate-associated lymphoproliferative disorders 12.4
36 epstein-barr virus-associated malignant lymphoproliferative disorder 12.4
37 chronic lymphoproliferative disorder of natural killer cells 12.4
38 post-transplant lymphoproliferative disease 12.2
39 lymphoproliferative syndrome 12.1
40 autoimmune lymphoproliferative syndrome, type v 11.6
41 castleman disease 11.6
42 lymphoproliferative syndrome 2 11.6
43 necrobiotic xanthogranuloma 11.6
44 lymphoproliferative syndrome, x-linked, 1 11.5
45 hairy cell leukemia 11.5
46 follicular lymphoma 11.5
47 multicentric castleman disease 11.4
48 autoimmune lymphoproliferative syndrome 11.4
49 pityriasis lichenoides 11.4
50 waldenstroem's macroglobulinemia 11.4

Graphical network of the top 20 diseases related to Systemic Epstein-Barr Virus-Positive T-Cell Lymphoma of Childhood:



Diseases related to Systemic Epstein-Barr Virus-Positive T-Cell Lymphoma of Childhood

Symptoms & Phenotypes for Systemic Epstein-Barr Virus-Positive T-Cell Lymphoma of...

GenomeRNAi Phenotypes related to Systemic Epstein-Barr Virus-Positive T-Cell Lymphoma of Childhood according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-1 9.17 DDX3X TIA1
2 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-2 9.17 CD2 DDX3X GZMB TIA1
3 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-3 9.17 DDX3X

Drugs & Therapeutics for Systemic Epstein-Barr Virus-Positive T-Cell Lymphoma of...

Drugs for Systemic Epstein-Barr Virus-Positive T-Cell Lymphoma of Childhood (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 218)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mycophenolic acid Approved Phase 4 24280-93-1 446541
2
Azathioprine Approved Phase 4 446-86-6 2265
3 Immunologic Factors Phase 4
4 Antirheumatic Agents Phase 4
5 Anti-Infective Agents Phase 4
6 Immunosuppressive Agents Phase 4
7 Antimetabolites Phase 4
8 Hematinics Phase 4
9 Epoetin alfa Phase 4 113427-24-0
10 Anti-Bacterial Agents Phase 4
11 Antibiotics, Antitubercular Phase 4
12 Antitubercular Agents Phase 4
13
Iron Approved, Experimental Phase 3 15438-31-0, 7439-89-6 27284 23925
14
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
15
Amitriptyline Approved Phase 3 50-48-6 2160
16
Perphenazine Approved Phase 3 58-39-9 4748
17
Baclofen Approved Phase 3 1134-47-0 2284
18
Prednisolone phosphate Approved, Vet_approved Phase 2, Phase 3 302-25-0
19
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3 83-43-2 6741
20
Methylprednisolone hemisuccinate Approved Phase 2, Phase 3 2921-57-5
21
Prednisolone Approved, Vet_approved Phase 2, Phase 3 50-24-8 5755
22 Prednisolone acetate Approved, Vet_approved Phase 2, Phase 3 52-21-1
23
Methoxsalen Approved Phase 3 298-81-7 4114
24
Darbepoetin alfa Approved, Investigational Phase 3 11096-26-7, 209810-58-2
25
Everolimus Approved Phase 3 159351-69-6 70789204 6442177
26
Pancrelipase Approved, Investigational Phase 3 53608-75-6
27
Blinatumomab Approved, Investigational Phase 3 853426-35-4
28
rituximab Approved Phase 3 174722-31-7 10201696
29
Etoposide Approved Phase 3 33419-42-0 36462
30
Methylcobalamin Approved, Investigational Phase 3 13422-55-4
31
Hydroxocobalamin Approved Phase 3 13422-51-0 15589840 11953898
32
Melphalan Approved Phase 3 148-82-3 460612 4053
33
Cytarabine Approved, Experimental, Investigational Phase 3 147-94-4, 65-46-3 6253
34
Busulfan Approved, Investigational Phase 2, Phase 3 55-98-1 2478
35
Ponatinib Approved, Investigational Phase 3 943319-70-8 24826799
36
Carmustine Approved, Investigational Phase 3 154-93-8 2578
37
Ginseng Approved, Investigational, Nutraceutical Phase 3 50647-08-0
38
Cyanocobalamin Approved, Nutraceutical Phase 3 68-19-9 44176380
39
Prednisolone hemisuccinate Experimental Phase 2, Phase 3 2920-86-7
40
Cobalamin Experimental Phase 3 13408-78-1 6857388
41 Antilymphocyte Serum Phase 3
42 Cyclosporins Phase 2, Phase 3
43 Ferric Oxide, Saccharated Phase 3
44 Gastrointestinal Agents Phase 2, Phase 3
45 Hemostatics Phase 3
46 Antiemetics Phase 2, Phase 3
47 Excitatory Amino Acid Antagonists Phase 3
48 Antidepressive Agents Phase 3
49 Adrenergic Agents Phase 3
50 GABA Agonists Phase 3

Interventional clinical trials:

(show top 50) (show all 286)
# Name Status NCT ID Phase Drugs
1 Evaluation of the Immune Response After Vaccination Against Hepatitis B in Patients With Indolent Lymphoproliferative Disorders With no Treatment. Unknown status NCT01698866 Phase 4
2 Safety, Immunogenicity And Efficacy Of Vaccination In Military Personnel Completed NCT01807780 Phase 4
3 Quality of Life Related Response to Treatment in Anemic Cancer Patients Receiving Recormon and Efficacy of the Drug Dosage 30,000 IU Once Weekly in Patients With Lymphoproliferative Disorders Completed NCT00776425 Phase 4 Epoetin beta
4 A Single-arm Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin Lymphoma Who Are Not Suitable for Stem Cell Transplantation or Multiagent Chemotherapy Completed NCT01990534 Phase 4 Brentuximab vedotin
5 Fludarabine, Cyclophosphamide, Doxorubicin and Rituximab for the Treatment of Post-transplant Lymphoproliferative Disease (PTLD) Completed NCT01088724 Phase 4 fludarabine, cyclophosphamide, doxorubicin, rituximab
6 A Randomized, Prospective, Multicenter Trial to Compare the Effect on Chronic Allograft Nephropathy Prevention of Mycophenolate Mofetil Versus Azathioprine as the Sole Immunosuppressive Therapy for Kidney Transplant Recipients Completed NCT00494741 Phase 4 mycophenolate mofetil;azathioprine
7 A Multi-Center, Open-Labelled, Pralatrexate Study in Asian Patients With Peripheral T-cell Lymphoma After Prior Therapy Recruiting NCT03150602 Phase 4 Pralatrexate
8 Randomised Controlled Open-label Study to Evaluate Efficacy & Safety of Intravenous Ferric Carboxymaltose Versus no Treatment in Anaemic Subjects With Multiple Myeloma & Iron Restricted Erythropoiesis Receiving Chemotherapy Terminated NCT01100879 Phase 4 Ferric carboxymaltose
9 Cytotoxic T Cell Therapy for Post Transplant Lymphoproliferative Disease: Randomized Controlled Trial in Transplant Recipients Unknown status NCT00033475 Phase 3
10 Evaluation of Plasmatic Levels of Busulfan in Patients Undergoing Hematopoietic Stem Cell Transplantation Unknown status NCT01800643 Phase 2, Phase 3
11 Multi-Centre Prospective Randomized Study on the Use of Two Different Doses of Rabbit Anti-Thymocyte Globulin for GVHD Prevention in Paediatric Patients With Haematological Malignancies Given an Unrelated Donor Haematopoietic Stem Cell Transplantation Unknown status NCT00934557 Phase 3 ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius
12 Phase 3 Study of Recombinant Erythropoetin and Adjuvant I.V. Iron Therapy of Anemic Patients With Lymphoproliferative Disorders Completed NCT00145652 Phase 3 Neo-Recormon and Venofer
13 Randomized Study for Comparison of Reduced Intensity Conditioning Protocols Containing Either Thymoglobuline or Alemtuzumab in Patients Undergoing Allogeneic Transplant From Voluntary Unrelated Donors Completed NCT00354120 Phase 2, Phase 3 Alentuzumab;Globulina antilinfocitaria
14 Predictive Value of the "Cytocapacity Test" Following a Single-dose of rHu-G-CSF in Patients With Lymphoproliferative Diseases and High-dose Therapy Completed NCT01085058 Phase 2, Phase 3 lenograstim
15 A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer Completed NCT00058331 Phase 3
16 The Use of Topical Baclofen, Amitriptyline HCI, and Ketamine (BAK) in a PLO Gel vs. Placebo for the Treatment of Chemotherapy Induced Peripheral Neuropathy: A Phase III Randomized Double-Blind Placebo Controlled Study Completed NCT00516503 Phase 3 baclofen/amitriptyline/ketamine gel
17 Randomised Controlled Open-label Study to Evaluate Efficacy & Safety of Intravenous Ferric Carboxymaltose Versus no Treatment in Anaemic Subjects With Lymphoid Malignancies & Functional Iron Deficiency Receiving Chemotherapy Completed NCT01101399 Phase 3 Ferric carboxymaltose
18 An International, Multicenter, Randomized, Double-Blind Study of Vorinostat (MK0683) or Placebo in Combination With Bortezomib in Patients With Multiple Myeloma Completed NCT00773747 Phase 3 vorinostat;bortezomib;placebo to vorinostat
19 A Double-Blind Study Of Nutritional Intervention For The Treatment Of Cancer Cachexia Using Juven® Nutritional Supplement Completed NCT00053053 Phase 3
20 A Multi-center, Randomized Study on Oral 8-methoxypsoralen Plus UVA With or Without Maintenance Therapy in Mycosis Fungoides EORTC/ISCL Stage IA to IIB Completed NCT01686594 Phase 3 8-methoxypsoralen
21 The Unrelated Donor Marrow Transplantation Trial Completed NCT00003187 Phase 2, Phase 3 cyclophosphamide;cyclosporine;cytarabine;methotrexate;methylprednisolone
22 A Randomized, Open-Label, Multicenter Study Of Darbepoetin Alfa Administered Once Every Two Weeks (Q2W) Compared With rHuEPO Administered Once Every Week (QW) For The Treatment Of Anemia In Subjects With Non-Myeloid Malignancies Receiving Multiple Chemotherapy Completed NCT00070382 Phase 3 darbepoetin alfa;epoetin alfa
23 A Phase III, Randomized Study of the Effects of Parenteral Iron, Oral Iron, or No Iron Supplementation on the Erythropoietic Response to Darbepoetin Alfa for Cancer Patients With Chemotherapy-Associated Anemia Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
24 Preparatory Aid to Improve Decision Making About Cancer Clinical Trials (PRE-ACT) Completed NCT00750009 Phase 3
25 The Use of American Ginseng (Panax Quinquefolius) to Improve Cancer-Related Fatigue: A Randomized, Double-Blind, Placebo-Controlled Phase III Study Completed NCT00719563 Phase 3 American ginseng
26 Phase III Randomized Trial of an Opioid Titration Order Sheet Compared to Standard of Care in Patients With Cancer Related Pain. Completed NCT00666211 Phase 3
27 Open-label Extension Study With Tadekinig Alfa (r-hIL-18BP) to Monitor Safety and Tolerability in Patients With IL-18 Driven Monogenic Autoinflammatory Conditions: NLRC4 Mutation and XIAP Deficiency Recruiting NCT03512314 Phase 3 Tadekinig alfa
28 Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal Trial With Tadekinig Alfa (r-hIL-18BP) in Patients With IL-18 Driven Monogenic Autoinflammatory Conditions: NLRC4 Mutation and XIAP Deficiency Recruiting NCT03113760 Phase 3 Tadekinig alfa
29 Multicenter, Open Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Subjects With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure of Rituximab or Rituximab and Chemotherapy Recruiting NCT03394365 Phase 3
30 Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Allogeneic Hematopoietic Cell Transplant Subjects With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure of Rituximab Recruiting NCT03392142 Phase 3
31 Phase III Multicenter Open-label Randomized Clinical Trial Comparing Everolimus and Low Dose Tacrolimus to Tacrolimus and Mycophenolate Mofetil at 6 mo Post-Transplant to Prevent Long-term Complications After Pediatric Heart Transplantation Recruiting NCT03386539 Phase 3 Everolimus;Tacrolimus;Mycophenolate Mofetil
32 Phase 3 Trial to Investigate the Efficacy, Safety, and Tolerability of Blinatumomab as Consolidation Therapy Versus Conventional Consolidation Chemotherapy in Pediatric Subjects With HR First Relapse B-precursor ALL Active, not recruiting NCT02393859 Phase 3 Blinatumomab;Conventional Consolidation Chemotherapy
33 A Multi-center, Randomized, Phase 3 Study of Sequential Pralatrexate Versus Observation in Patients With Previously Undiagnosed Peripheral T-cell Lymphoma Who Have Achieved an Objective Response Following Initial Treatment With CHOP-based Chemotherapy Terminated NCT01420679 Phase 3 Pralatrexate Injection
34 In-vivo T-cell Depletion and Hematopoietic Stem Cell Transplantation for Life-Threatening Immune Deficiencies and Histiocytic Disorders Terminated NCT00176826 Phase 2, Phase 3 Myeloablative conditioning regimen
35 A Phase 3 Randomized,Open-Label Study of Ponatinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase Terminated NCT01650805 Phase 3 ponatinib;imatinib (Gleevec/ Glivec)
36 SPINOZA / שפינוזה. Study With Preparatory INduction Of Zevalin in Aggressive Lymphoma. A Randomized Phase 3 Study of BEAM Versus 90Yttrium Ibritumomab Tiuxetan (Zevalin) / BEAM in Patients Requiring ASCT for Relapsed DLBCL Terminated NCT02366663 Phase 3 Carmustine;Etoposide;Cytarabine;Melphalan
37 Phase II Trial of Rituximab in Patients With B-Cell Lymphoproliferative Disorders Associated With Pharmacologic Immunosuppression Unknown status NCT00003716 Phase 2
38 A Pilot Study to Assess the Feasibility of Unrelated Umbilical Cord Blood Transplantation With Coinfusion of Third-party Mesenchymal Stem Cells After Myeloablative or Nonmyeloablative Conditioning in Patients With Hematological Malignancies Unknown status NCT01092026 Phase 1, Phase 2
39 A Phase II Study of the Therapeutic Effects Of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies Completed NCT01498484 Phase 2
40 A Multicenter Phase II Study Of BMS 247550 (Epothilone B Analogue) In Indolent Lymphoproliferative Disorders Completed NCT00052572 Phase 2 ixabepilone
41 Phase II Study of PS-341 in Low Grade Lymphoproliferative Disorders Completed NCT00023764 Phase 2 bortezomib
42 A Pilot Study of the Combination of Retinoic Acid and Interferon-Alpha2a for the Treatment of Lymphoproliferative Disorders in Children With Immunodeficiency Syndromes Completed NCT00001438 Phase 2 all-trans-retinoic acid with IFN-alpha2a
43 A Phase II Multi-Dose Study of SGN-30 (Anti-CD30 mAb) in Patients With Primary Cutaneous Anaplastic Large Cell Lymphoma, Large Cell Transformation of Mycosis Fungoides, and Lymphomatoid Papulosis Completed NCT00099255 Phase 2 SGN-30
44 A Phase II Study of SGN-40 (Anti-huCD40 mAb) in Patients With Relapsed Diffuse Large B-Cell Lymphoma (DLBCL) Completed NCT00435916 Phase 2 SGN-40
45 An Open-label, Single-arm Phase II Study of RAD001 in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma Completed NCT01022996 Phase 2 Everolimus (RAD001)
46 Open Label Multicenter Study of Eltrombopag for the Treatment of Immune ThrombocytoPenia (ITP) Secondary to Chronic Lymphoproliferative Disorders (LPDs) Completed NCT01610180 Phase 2 Eltrombopag Olamine
47 An Open Label, Multicenter, Exploratory Phase II Study to Evaluate the Efficacy, Safety, and Tolerability of the BiTE® Antibody Blinatumomab in Adult Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL) Completed NCT01209286 Phase 2
48 Phase I/II Study of Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancy, Using MHC Identical or Near Identical Donors and Sub-Myeloablative Conditioning With CAMPATH 1H (DIMSUM) Completed NCT00048412 Phase 1, Phase 2 FLUDARABINE;CAMPATH 1H;FK50
49 A Phase 1/2, Multi-Dose Study of SGN-40 (Anti-huCD40 mAb) in Patients With Chronic Lymphocytic Leukemia Completed NCT00283101 Phase 1, Phase 2 SGN-40 (anti-huCD40 mAb)
50 Treatment of Patients With Posttransplant Lymphoproliferative Disorder (PTLD) With a Sequential Treatment Consisting of Anti-CD20 Antibody Rituximab and CHOP+GCSF Chemotherapy (PTLD-1/3) Completed NCT00590447 Phase 2 rituximab monotherapy;sequential R-CHOP

Search NIH Clinical Center for Systemic Epstein-Barr Virus-Positive T-Cell Lymphoma of Childhood

Cochrane evidence based reviews: lymphoproliferative disorders

Genetic Tests for Systemic Epstein-Barr Virus-Positive T-Cell Lymphoma of...

Anatomical Context for Systemic Epstein-Barr Virus-Positive T-Cell Lymphoma of...

MalaCards organs/tissues related to Systemic Epstein-Barr Virus-Positive T-Cell Lymphoma of Childhood:

40
T Cells, B Cells, Bone Marrow, Bone, Myeloid, Lymph Node, Kidney

Publications for Systemic Epstein-Barr Virus-Positive T-Cell Lymphoma of...

Articles related to Systemic Epstein-Barr Virus-Positive T-Cell Lymphoma of Childhood:

# Title Authors PMID Year
1
Systemic Epstein-Barr virus-positive T-cell lymphoma of childhood. 61
31886782 2019
2
Systemic Epstein-Barr Virus-positive T-Cell Lymphoma of Childhood Presentation With Hemophagocytosis. 61
30870386 2019
3
Young adult onset systemic Epstein-Barr virus-positive T-cell lymphoproliferative disorders of childhood. 61
26062673 2015
4
Hydroa vacciniforme-like lymphoma: a chronic EBV+ lymphoproliferative disorder with risk to develop a systemic lymphoma. 61
23982171 2013

Variations for Systemic Epstein-Barr Virus-Positive T-Cell Lymphoma of...

Expression for Systemic Epstein-Barr Virus-Positive T-Cell Lymphoma of...

Search GEO for disease gene expression data for Systemic Epstein-Barr Virus-Positive T-Cell Lymphoma of Childhood.

Pathways for Systemic Epstein-Barr Virus-Positive T-Cell Lymphoma of...

Pathways related to Systemic Epstein-Barr Virus-Positive T-Cell Lymphoma of Childhood according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.97 NCAM1 GZMB CD8A CD2
2 11.67 NCAM1 CD8A CD2
3 11.5 NCAM1 CD8A CD2
4 11.25 CR2 CD8A CD7 CD2
5
Show member pathways
11.15 GZMB CD8A
6 10.83 NCAM1 GZMB CD8A CD7

GO Terms for Systemic Epstein-Barr Virus-Positive T-Cell Lymphoma of...

Cellular components related to Systemic Epstein-Barr Virus-Positive T-Cell Lymphoma of Childhood according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasmic stress granule GO:0010494 8.62 TIA1 DDX3X

Biological processes related to Systemic Epstein-Barr Virus-Positive T-Cell Lymphoma of Childhood according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 9.62 DDX3X CR2 CD8A CD7
2 apoptotic process GO:0006915 9.56 TIA1 GZMB DDX3X CD2
3 negative regulation of translation GO:0017148 9.33 TIA1 GZMB DDX3X
4 protein localization to cytoplasmic stress granule GO:1903608 8.96 TIA1 DDX3X
5 T cell activation GO:0042110 8.8 CD8A CD7 CD2

Molecular functions related to Systemic Epstein-Barr Virus-Positive T-Cell Lymphoma of Childhood according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 poly(A) binding GO:0008143 8.62 TIA1 DDX3X

Sources for Systemic Epstein-Barr Virus-Positive T-Cell Lymphoma of...

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....